Trevi Therapeutics Inc
$ 15.40
1.12%
20 Apr - close price
- Market Cap 1,955,490,000 USD
- Current Price $ 15.40
- High / Low $ 16.12 / 15.05
- Stock P/E N/A
- Book Value 1.43
- EPS -0.32
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.30 %
- 52 Week High 16.12
- 52 Week Low 5.38
About
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$21.55
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-25 | 2025-11-13 | 2025-08-07 | 2025-05-05 | 2025-03-18 | 2024-11-06 | 2024-08-08 | 2024-05-07 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.06 | -0.08 | -0.09 | -0.09 | -0.11 | -0.13 | -0.12 | -0.11 | -0.08 | -0.08 | -0.07 | -0.06 |
| Estimated EPS | -0.0985 | -0.1 | -0.1 | -0.09 | -0.1171 | -0.12 | -0.11 | -0.09 | -0.09 | -0.09 | -0.08 | -0.07 |
| Surprise | 0.0385 | 0.02 | 0.01 | 0 | 0.0071 | -0.01 | -0.01 | -0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Surprise Percentage | 39.0863% | 20% | 10% | 0% | 6.0632% | -8.3333% | -9.0909% | -22.2222% | 11.1111% | 11.1111% | 12.5% | 14.2857% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRVI
2026-04-20 19:39:08
Trevi Therapeutics, Inc. announced the closing of its $173 million underwritten public offering of 13,340,000 shares of common stock at $13.00 per share, which includes the full exercise of the underwriters' option to purchase additional shares. The company, a clinical-stage biopharmaceutical firm, is developing Haduvio™ for chronic cough associated with idiopathic pulmonary fibrosis and other lung diseases. Morgan Stanley, Leerink Partners, Cantor, and Stifel acted as joint book-running managers.
2026-04-20 19:39:08
Trevi Therapeutics (Nasdaq: TRVI) closed an underwritten public offering, raising approximately $173 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase additional shares, totaling 13,340,000 common shares sold at $13.00 per share. Proceeds are intended to fund Haduvio’s Phase 3 and Phase 2b trials and extend the company's financial runway.
2026-04-18 08:39:44
Several prominent stocks, including Netflix, Trevi Therapeutics, Fluence Energy, and Alcoa Corporation, experienced declines in pre-market trading on Friday. Netflix's shares fell sharply after the company reported better-than-expected Q1 2026 results but issued a weak Q2 forecast and announced chairman Reed Hastings would not seek re-election. Trevi Therapeutics also saw a drop after pricing a significant common stock offering for Haduvio development.
2026-04-18 00:39:08
Trevi Therapeutics, Inc. has announced a proposed underwritten public offering of $150,000,000 of its common stock. The company also intends to grant underwriters a 30-day option to purchase an additional $22,500,000 in shares. This offering is subject to market and other conditions, and there is no assurance as to its completion or terms.
2026-04-17 20:11:17
Trevi Therapeutics is offering 11.6 million shares of common stock at $13.00 per share, aiming to raise aggregate gross proceeds of $150.8 million. The underwriters have an option to purchase an additional 1.74 million shares. The net proceeds, estimated between $141.1 million and $162.4 million depending on the option exercise, will primarily fund the clinical development of Haduvio for chronic cough in various conditions and support operations through 2029.
2026-04-17 18:39:03
D. Boral Capital has reiterated its "Buy" rating for Trevi Therapeutics (NASDAQ:TRVI), setting a $19.00 price target that suggests a 25.45% upside. This comes as the company's stock traded up by 4.2% to $15.15 and reported stronger-than-expected quarterly EPS of -$0.06 against a consensus of -$0.10. Institutional investors hold a significant 95.8% stake in the company, reflecting strong confidence in its prospects.
